Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
Ist Teil von
Clinical pharmacology and therapeutics, 2012-09, Vol.92 (3), p.306-320
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2012
Link zum Volltext
Quelle
Wiley Online Library All Journals
Beschreibungen/Notizen
Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.
Clinical Pharmacology & Therapeutics (2012); 92 3, 306–320. doi:10.1038/clpt.2012.77